Metabolic Research
Lot Verification
Variant-specific documentation
Traceable Lots
VBL lot identification
Primary Literature
Peer-reviewed sources
Research Use Only
Laboratory research materials
Scientific Specifications
Reference characteristics for laboratory research materials.
CAS Number
2023788-19-2
Purity
≥98%
Molecular Formula
C225H348N48O68
Molecular Weight
4813.5
Appearance
White lyophilized powder
Storage
-20°C
Research Classification
Research Use Only (RUO). Not for human or veterinary use.
SCIENTIFIC OVERVIEW
Scientific background and research classification for this laboratory reference material.
Lyophilized Peptide
Laboratory Research
Receptor Pharmacology
Energy Homeostasis
Glucose Metabolism
Weight Management
Mechanism of Action
Molecular interaction profile describing how this research material engages receptor systems and influences downstream biological signaling pathways.
- Glucagon-Like Peptide-1 Receptor (GLP-1R)
- Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR)
- GLP-1 Signaling
- GIP Signaling
- Insulin Signaling
- Glucose Uptake
- Lipolysis
- Endocrine System
- Gastrointestinal System
- Central Nervous System
- Metabolic System
Research Documentation
Laboratory documentation is presented when available for the selected product specification and current lot.
Batch Verified
Independent Batch Verification
Identity
Purity
Endotoxin
Fentanyl
Independent laboratory verification for this batch:
- Identity Confirmation
- HPLC Purity Analysis
- Net Peptide Content
- Endotoxin Testing
- Analytical Chromatogram
- Independent Laboratory Verification
Laboratory documentation for the current lot is being completed.
Scientific References
Peer-Reviewed Literature
Explore published literature, clinical investigations, and foundational scientific research.
View References →Laboratory Resources
Technical Guidance
Storage guidance, handling recommendations, analytical methods, and laboratory best practices.
Related Research
Companion Materials
Discover complementary research materials frequently studied alongside this compound.
Research Center
Scientific literature, laboratory resources, and related materials curated to support research involving this research material.
Scientific References
Peer-Reviewed Literature
Explore curated publications from peer-reviewed journals including clinical investigations, mechanistic studies, and foundational scientific literature.
Browse References →Scientific Dossier
Deeper Technical Treatment
Comprehensive scientific documentation including literature review, mechanism, pharmacology, and study data for this research material.
Laboratory Resources
Technical Guidance
Storage guidance, handling information, analytical standards, research policies, and laboratory support documentation.
Research Library
Curated peer-reviewed literature selected to provide scientific context for this research material.
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Discovery and characterization of LY3298176 (tirzepatide): engineered dual GIPR/GLP-1R agonist peptide with C20 fatty-diacid acylation; describes in vitro receptor pharmacology, preclinical glucose and body-weight effects, and first clinical proof-of-concept data.
Velora Research Insight
The primary discovery reference for this material — establishes the molecule's dual-agonist design rationale and foundational pharmacology used across incretin research.
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Detailed receptor pharmacology showing tirzepatide binds GIPR with affinity comparable to native GIP while engaging GLP-1R more weakly, with biased signaling favoring cAMP over beta-arrestin recruitment at GLP-1R.
Velora Research Insight
Defines the imbalanced/biased receptor profile that underpins the dossier's mechanism-of-action treatment; core reference for receptor-bias research designs.
Structural determinants of dual incretin receptor agonism by tirzepatide
Structural (cryo-EM) analysis of tirzepatide-bound incretin receptor complexes identifying the molecular determinants that allow one peptide to activate both GIPR and GLP-1R.
Velora Research Insight
Provides the structural basis for the dual-agonism claims in this dossier; anchor reference for structure-function research.
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Phase 3 SURPASS-1 monotherapy trial in type 2 diabetes: dose-dependent reductions in HbA1c and body weight versus placebo across 5/10/15 mg once-weekly regimens.
Velora Research Insight
Primary clinical evidence for glycemic pharmacodynamics of the dual agonist class; contextualizes translational research on incretin co-agonism.
Tirzepatide Once Weekly for the Treatment of Obesity
Phase 3 SURMOUNT-1 trial in adults with obesity or overweight: substantial dose-dependent body-weight reductions with once-weekly tirzepatide versus placebo over 72 weeks.
Velora Research Insight
Primary clinical evidence for energy-homeostasis/body-weight pharmacology of dual incretin agonism; supports the dossier's weight-management research framing.